In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Subodh Verma
Speaker
Subodh Verma
Subodh Verma Subodh Verma

St. Michael's Hospital, Toronto (Canada)

Speciality : Pharmacology and Pharmacotherapy

Dr. Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery. Dr. Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in 7 ongoing global heart failure trials.

17 presentations from this speaker

Connecting with the speakers - Questions and answers

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : L Ryden (Stockholm,SE), S Verma (Toronto,CA), M Kosiborod (Kansas,US)
  • Sponsored by Novo Nordisk A/S

Emerging knowledge on cardiorenal protection.

Event : Heart Failure 2019

  • Session : Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)
  • Speaker : S Verma (Toronto,CA)
  • Organised by the Sahlgrenska Academy, University of Gothenburg, Sweden, supported with an educational grant from AstraZeneca. Course Director: Professor Karl Swedberg

From classroom to clinic: sodium–glucose co-transporter 2 inhibitor evidence in practice.

Event : Heart Failure 2019

  • Session : Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)
  • Speaker : S Verma (Toronto,CA), M Cowie (London,GB), S Wiviott (Boston,US), A Mebazaa (Paris,FR)
  • Organised by the Sahlgrenska Academy, University of Gothenburg, Sweden, supported with an educational grant from AstraZeneca. Course Director: Professor Karl Swedberg

Gazing into the future opportunities of glucagon-like peptide-1 receptor agonists in cardiovascular disease

Event : ESC Congress 2019

  • Session : Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
  • Speaker : S Verma (Toronto,CA)
  • Sponsored by Novo Nordisk A/S

Q&A - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.

Event : Heart Failure 2019

  • Session : Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)
  • Speaker : S Verma (Toronto,CA), M Cowie (London,GB), A Mebazaa (Paris,FR), M Pfeffer (Boston,US)
  • Organised by the Sahlgrenska Academy, University of Gothenburg, Sweden, supported with an educational grant from AstraZeneca. Course Director: Professor Karl Swedberg

Questions and answers

Event : ESC Congress 2019

  • Session : Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)
  • Speaker : F Ruschitzka (Zurich,CH), M Bonaca (Boston,US), S Verma (Toronto,CA), M Kosiborod (Kansas,US)
  • Supported by an unrestricted educational grant from AstraZeneca

SGLT2 inhibitors: uncovering the mechanisms of cardiovascular risk reduction

Event : ESC Congress 2019

  • Session : Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)
  • Speaker : S Verma (Toronto,CA)
  • Supported by an unrestricted educational grant from AstraZeneca

The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension

Event : ESC Congress 2019

  • Session : Novel pharmacological targets in vascular disease
  • Speaker : S Verma (Toronto,CA)

Why could patients with heart failure and T2DM benefit from SGLT2 inhibition?

Event : Heart Failure 2019

  • Session : Heart Failure, diabetes & SGLT2 inhibition: time to change practice?
  • Speaker : S Verma (Toronto,CA)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim

Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .

Event : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE), D McGuire (Dallas,US), JA Udell (Toronto,CA), S Verma (Toronto,CA), N Sattar (Glasgow,GB)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Empagliflozin prevention of heart failure development in diabetes is associated with an improvement in cardiac energy producition

Event : ESC Congress 2018

  • Session : Targeting reverse remodelling in heart failure
  • Speaker : S Verma (Toronto,CA)

Exploring the effects of SGLT2 inhibition in ongoing trials.

Event : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : S Verma (Toronto,CA)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

New insights into glucagon-like peptide-1 receptor agonist treatment considerations.

Event : ESC Congress 2018

  • Session : Discussion: Glucagon-like peptide-1 receptor agonists and changing paradigms in clinical practice
  • Speaker : S Verma (Toronto,CA)
  • Sponsored by Novo Nordisk A/S

Perspective on glucagon-like peptide-1 receptor agonists in type 2 diabetes and cardiovascular disease: Interactive discussion.

Event : ESC Congress 2018

  • Session : Discussion: Glucagon-like peptide-1 receptor agonists and changing paradigms in clinical practice
  • Speaker : BM Scirica (Boston,US), S Verma (Toronto,CA), M Pfeffer (Boston,US)
  • Sponsored by Novo Nordisk A/S

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are